Cargando…
Circulating tumor DNA based minimal residual disease detection and adjuvant treatment decision-making for muscle-invasive bladder cancer guided by modern clinical trials
Up to 430,000 cases of bladder cancer are diagnosed each year worldwide. A proposed method for non-invasive monitoring has been to utilize a “liquid biopsy.” Liquid biopsy has been proposed as a non-invasive method of testing biomarkers in bodily fluids in order to detect and survey cancer. The liqu...
Autores principales: | Nawaf, Cayce, Shiang, Alexander, Chauhan, Pradeep S., Chaudhuri, Aadel A., Agarwal, Gautum, Smith, Zachary L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495651/ https://www.ncbi.nlm.nih.gov/pubmed/37657155 http://dx.doi.org/10.1016/j.tranon.2023.101763 |
Ejemplares similares
-
Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA
por: Semenkovich, Nicholas P, et al.
Publicado: (2023) -
00005 Urine tumor DNA detects minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy
por: Chen, Kevin, et al.
Publicado: (2021) -
PACT: a pipeline for analysis of circulating tumor DNA
por: Webster, Jace, et al.
Publicado: (2023) -
Urine cell-free DNA multi-omics to detect MRD and predict survival in bladder cancer patients
por: Chauhan, Pradeep S., et al.
Publicado: (2023) -
Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study
por: Chauhan, Pradeep S., et al.
Publicado: (2021)